Can a wearable glucose sensor help young people with prediabetes turn things around?

NCT ID NCT05505565

Completed Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether using a continuous glucose monitor (CGM) alongside standard nutrition and activity advice can improve metabolic health in young people aged 11 and older who have prediabetes and are overweight. Participants wear the CGM intermittently to see how daily activities affect their blood sugar. The study measures changes in blood sugar control (HbA1c) and insulin resistance over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abbott Freestyle Libre 2 continuous glucose monitor
What this could lead to: If successful, this approach could offer a practical tool to help young people with prediabetes better manage their condition and prevent progression to type 2 diabetes.
What could go wrong: This is a small, early-stage study (54 participants) focused on feasibility and short-term changes, so results may not apply broadly. The device itself is not a treatment and carries minor risks like skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance Obesity obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSULIN RESISTANCE OBESITY PREDIABETES

Contacts and locations

Locations

Children's of Alabama

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.